康缘药业(600557.SH)：获得泻白散颗粒药品注册证书

Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) has received the drug registration certificate for Xiebaisan Granules from the National Medical Products Administration, which is expected to enhance the clinical application of traditional Chinese medicine and improve the company's market competitiveness in pediatric medication [1] Group 1: Product Approval - The drug's generic name is Xiebaisan Granules, with registration standard number YBZ00832025 and approval number Guoyao Zhunzi C20250016 [1] - Xiebaisan is effective in clearing lung heat and alleviating cough and asthma, specifically for pediatric patients with symptoms such as wheezing and cough [1] Group 2: Clinical Application - Xiebaisan has a long history of clinical use and is recognized for its efficacy and low adverse reactions, which supports its broader application in clinical settings [1] - The approval of Xiebaisan Granules is expected to promote the use of classical formulas in clinical practice, enhancing the level of traditional Chinese medicine services [1] Group 3: Market Impact - Pediatric medication is a key area for the company, and the approval of Xiebaisan Granules enriches its pediatric product lineup [1] - This development is anticipated to strengthen the company's market competitiveness and brand influence in the pediatric sector, laying a solid foundation for sustained profitability [1]